IFOSFAMIDE (IFEX)

Course overview

Ifosfamide is U.S. FDA-approved as third-line therapy for germ cell testicular cancer in adults, in combination with other antineoplastic agents and a prophylactic agent against hemorrhagic cystitis. It must be used cautiously in patients with renal impairment, leukopenia, granulocytopenia, multiple bone marrow metastases, or history of radiotherapy or cytotoxic (e.g., CISplatin) chemotherapy. This continuing education module is designed to give the reader/learner an increased understanding of ifosfamide. Readers may explore any or all of the topics. One contact hour of continuing education credit is available for those who successfully complete the post-test and evaluation form.